Nexus Surgical and Medicare Limited

As of June 30, 2026, Nexus Surgical and Medicare Limited carries a market capitalization of 114.91M, placing it among publicly traded companies globally. Its enterprise value stands at 114.91M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Nexus Surgical and Medicare Limited has 5.47M shares outstanding.

As of June 30, 2026, Nexus Surgical and Medicare Limited trades at a trailing price-to-earnings ratio of 14.58.

As of June 30, 2026, Nexus Surgical and Medicare Limited trades at an EV/EBITDA multiple of 11.44 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 1.32 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 11.49 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 114.91M versus a market cap of 114.91M, with the gap driven by net debt and cash on the balance sheet.

Over the twelve months ended June 30, 2026, Nexus Surgical and Medicare Limited recorded 2.69M in income tax expense. That works out to an effective tax rate of 25.44, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 10.57M, leaving 7.88M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 23, 2026, Nexus Surgical and Medicare Limited's stock has gained approximately 49.11% over the past 52 weeks. The 50-day moving average sits at 27.71, while the 200-day moving average is 21.08.

Over the twelve months ended June 30, 2026, Nexus Surgical and Medicare Limited generated 86.91M in revenue and converted that into 7.88M in net income, yielding earnings per share of 1.44. EBITDA reached 10.05M, while operating income came in at 10.00M.

Over the twelve months ended June 30, 2026, Nexus Surgical and Medicare Limited posted a gross margin of 68.83, reflecting its pricing power and cost economics. The operating margin of 11.51 and net profit margin of 9.07 provide insight into operational efficiency.